Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans

Circulation

Volumn 117, Issue 18, 2008, Pages 2369-2376

  Duez, Hélène ^a   Lamarche, Benoît ^b   Valéro, René ^a   Pavlic, Mirjana ^a   Proctor, Spencer ^c   Xiao, Changting ^a   Szeto, Linda ^a   Patterson, Bruce W ^d   Lewis, Gary F ^a,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Fatty acids; Lipids; Lipoproteins

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; GLYCEROL; HEPARIN; INTRALIPID; LEUCINE; SODIUM CHLORIDE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; FATTY ACID BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INTESTINE FUNCTION; LIVER CLEARANCE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM;

ADULT; APOLIPOPROTEIN B-48; FATTY ACIDS, NONESTERIFIED; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINES; LIPIDS; LIPOPROTEINS; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; TIME FACTORS;

EID: 43249122976     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.739888     Document Type: Article

References (53)

1. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453-458.
2. Lewis GF, Steiner G. Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in non-insulin-dependent diabetes mellitus. Diabet Metab Rev. 1996;12:37-56.
3. Curtin A, Deegan P, Owens D, Collins P, Johnson A, Tomkin GH. Elevated triglyceride-rich lipoproteins in diabetes: a study of apolipoprotein B-48. Acta Diabetol. 1996;33:205-210.
4. Schaefer EJ, McNamara JR, Shah PK, Nakajima K, Cupples LA, Ordovas JM, Wilson PW. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care. 2002;25:989-994.
5. Mero N, Syvanne M, Taskinen MR. Postprandial lipid metabolism in diabetes. Atherosclerosis. 1998;141(suppl 1):S53-S55.
6. Ohnishi H, Saitoh S, Takagi S, Ohata J, Isobe T, Kikuchi Y, Takeuchi H, Shimamoto K. Relationship between insulin-resistance and remnant-like particle cholesterol. Atherosclerosis. 2002;164:167-170.
7. Taniguchi A, Fukushima M, Sakai M, Miwa K, Makita T, Nagata I, Nagasaka S, Doi K, Okumura T, Fukuda A, Kishimoto H, Fukuda T, Nakaishi S, Tokuyama K, Nakai Y. Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care. 2000;23:1766-1769.
8. Haidari M, Leung N, Mahbub F, Uffelman KD, Kohen-Avramoglu R, Lewis GF, Adeli K. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance: evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and apoB48-containing lipoprotein overproduction. J Biol Chem. 2002;277:31646-31655.
9. Leung N, Naples M, Uffelman K, Szeto L, Adeli K, Lewis GF. Rosiglitazone improves intestinal lipoprotein overproduction in the fat-fed Syrian Golden hamster, an animal model of nutritionally-induced insulin resistance. Atherosclerosis. 2004;174:235-241.
10. Guo Q, Avramoglu RK, Adeli K. Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids. Metabolism. 2005;54:689-697.
11. Federico LM, Naples M, Taylor D, Adeli K. Intestinal insulin resistance and aberrant production of apolipoprotein b48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes. 2006;55:1316-1326.
12. Lewis GF, Uffelman K, Naples M, Szeto L, Haidari M, Adeli K. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. Endocrinology. 2005;146:247-255.
13. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM, Schaefer EJ. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis. 2001;154:229-236.
14. Mero N, Malmstrom R, Steiner G, Taskinen MR, Syvanne M. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis. 2000;150:167-177.
15. Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol. 2006;26:1357-1363.
16. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. J Lipid Res. 2007;48:1336-1342.
17. Kovacs P, Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab. 2005;19:625-635.
18. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201-229.
19. Byrne CD, Brindle NP, Wang, Hales CN. Interaction of non-esterified fatty acid and insulin in control of triacylglycerol secretion by Hep G2 cells. Biochem J. 1991;280(pt 1):99-104.
20. Byrne CD, Wang TW, Hales CN. Control of Hep G2-cell triacylglycerol and apolipoprotein B synthesis and secretion by polyunsaturated non-esterified fatty acids and insulin. Biochem J. 1992;288(pt 1):101-107.
21. Cianflone KM, Yasruel Z, Rodriguez MA, Vas D, Sniderman AD. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J Lipid Res. 1990;31:2045-2055.
22. White AL, Graham DL, LeGros J, Pease RJ, Scott J. Oleate-mediated stimulation of apolipoprotein B secretion from rat hepatoma cells: a function of the ability of apolipoprotein B to direct lipoprotein assembly and escape presecretory degradation. J Biol Chem. 1992;267:15657-15664.
23. Dixon JL, Furukawa S, Ginsberg HN. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Biol Chem. 1991;266:5080-5086.
24. Arbeeny CM, Meyers DS, Bergquist KE, Gregg RE. Inhibition of fatty acid synthesis decreases very low density lipoprotein secretion in the hamster. J Lipid Res. 1992;33:843-851.
25. Sparks JD, Collins HL, Sabio I, Sowden MP, Smith HC, Cianci J, Sparks CE. Effects of fatty acids on apolipoprotein B secretion by McArdle RH-7777 rat hepatoma cells. Biochim Biophys Acta. 1997;1347:51-61.
26. Lin Y, Smit MJ, Havinga R, Verkade HJ, Vonk RJ, Kuipers F. Differential effects of eicosapentaenoic acid on glycerolipid and apolipoprotein B metabolism in primary human hepatocytes compared to HepG2 cells and primary rat hepatocytes. Biochim Biophys Acta. 1995;1256:88-96.
27. Zhang YL, Hernandez-Ono A, Ko C, Huang LS, Ginsberg HN. Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids, I: differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. J Biol Chem. 2004;279:19362-19374.
28. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest. 1995;95:158-166.
29. Lewis GF. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol. 1997;8:146-153.
30. Steiner G, Poapst ME, Davidson JK. Production of chylomicron-like lipoproteins from endogenous lipid by the intestine and liver of diabetic dogs. Diabetes. 1975;24:263-271.
31. Lewis GF, Naples M, Uffelman K, Leung N, Szeto L, Adeli K. Intestinal lipoprotein production is stimulated by an acute elevation of plasma free fatty acids in the fasting state: studies in insulin-resistant and insulin-sensitized Syrian golden hamsters. Endocrinology. 2004;145:5006-5012.
32. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine: effect of fasting and feeding. J Clin Invest. 1990;85:804-811.
33. Batal R, Tremblay M, Barrett PH, Jacques H, Fredenrich A, Mamer O, Davignon J, Cohn JS. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res. 2000;41:706-718.
34. Lookene A, Skottova N, Olivecrona G. Interactions of lipoprotein-lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat)(R). Eur J Biochem. 1994;222:395-403.
35. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
36. Dwyer KP, Barrett PHR, Chan D, Foo JI, Watts GF, Croft KD. Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins. J Lipid Res. 2002;43:344-349.
37. Cobelli C, Toffolo G, Foster DM. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am J Physiol. 1992;262:E968-E975.
38. Vine DF, Takechi R, Russell JC, Proctor SD. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome. Atherosclerosis. 2007;190:282-290.
39. Karpe F, Hamsten A, Uffelma, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Meth. 2007;39:175-191.
40. Deleted in proof.
41. Hussain MM, Fatma S, Pan X, Iqbal J. Intestinal lipoprotein assembly. Curr Opin Lipidol. 2005;16:281-285.
42. Gangl A, Ockner RK. Intestinal metabolism of plasma free fatty acids: intracellular compartmentation and mechanisms of control. J Clin Invest. 1975;55:803-813.
43. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87:507-520.
44. Heath RB, Karpe F, Milne RW, Burdge GC, Wootton SA, Frayn KN. Selective partitioning of dietary fatty acids into the VLDL TG pool in the early postprandial period. J Lipid Res. 2003;44:2065-2072.
45. Heath RB, Karpe F, Milne RW, Burdge GC, Wootton SA, Frayn KN. Dietary fatty acids make a rapid and substantial contribution to VLDL-triacylglycerol in the fed state. Am J Physiol. 2007;292:E732-E739.
46. Barrows BR, Parks E. Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab. 2006;91:1446-1452.
47. Hodson L, Bickerton AST, McQuaid SE, Roberts R, Karpe F, Frayn KN, Fielding BA. The contribution of splanchnic fat to VLDL triglyceride is greater in insulin-resistant than insulin-sensitive men and women: studies in the postprandial state. Diabetes. 2007;56:2433-2441.
48. Parks E, Hellerstein MK. Recent advances in liver triacylglycerol and fatty acid metabolism using stable isotope labeling techniques. J Lipid Res. 2006;47:1651-1660.
49. Marsh JB, Welty FK, Lichtenstein AH, Lamon-Fava S, Schaefer EJ. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis. 2002;162:227-244.
50. Chan DC, Watts GF, Ng TW, Uchida Y, Sakai N, Yamashita S, Barrett PH. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem. 2005;51:578-585.
51. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med. 1999;246:341-355.
52. Brunzell JD, Hazzard WR, Porte D Jr, Bierman EL. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest. 1973;52:1578-1585.
53. Bjorkegren J, Packard CJ, Hamsten A, Bedford D, Caslake M, Foster L, Shepherd J, Stewart P, Karpe F. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res. 1996;37:76-86.